All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Cetuximab β Plus FOLFIRI Displays Significant Clinical Activity in First-Line mCRC

May 20th 2025

Cetuximab β was effective and safe in patients with RAS/BRAF wild-type metastatic colorectal cancer.

Experts Preview Key Presentations to Watch in Gynecologic Oncology at ASCO 2025

May 20th 2025

Experts highlight key abstracts and presentations to keep an eye on in gynecologic oncology at the 2025 ASCO Annual Meeting.

FDA Awards RMAT Designation to BCB-276 CAR T-Cell Therapy for Diffuse Intrinsic Pontine Glioma

May 19th 2025

The B7-H3–directed CAR T-cell therapy BCB-276 received RMAT designation for the treatment of patients with diffuse intrinsic pontine glioma.

postMONARCH ctDNA Analysis Underscores Benefit of Abemaciclib Plus Fulvestrant in HR+ Advanced Breast Cancer

May 19th 2025

An exploratory ctDNA analysis from postMONARCH highlighted the benefit of abemaciclib plus fulvestrant across HR-positive breast cancer subgroups.

FDA Approval of Perioperative Durvalumab Plus Chemo Supports the Efficacy of a Novel MIBC Management Approach

May 19th 2025

Matthew Galsky, MD, discusses the significance of the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in MIBC.

Duration of Overweight/Obesity During Treatment Linked to Worse Outcomes in Pediatric Leukemia Patients

May 19th 2025

Collaborative Roswell Park/Columbia research uncovers greater risk of relapse and complications, lower survival rates.

FDA Grants Fast Track Designation to DLL3-Targeted ADC ZL-1310 in ES-SCLC

May 19th 2025

The DLL3-targeted antibody-drug conjugate ZL-1310 has received FDA fast track designation for patients with extensive-stage small cell lung cancer.

Belantamab Mafodotin–Based Combos Win Japanese Approval for R/R Myeloma

May 19th 2025

Two belantamab mafodotin–based combinations have been approved in Japan for relapsed/refractory multiple myeloma.

Combination Regimens Offer Options in Frontline RCC as Novel Agents Advance Through Pipeline

May 19th 2025

During an OncLive Peer Exchange filmed during ASCO GU, expert investigators discussed significant updates in the RCC space.

Tucatinib/Trastuzumab Yields Durable Responses in HER2-Mutated Metastatic Breast Cancer

May 19th 2025

Final analysis of SGNTUC-019 showed a 41.9% ORR, an 80.6% DCR, and a 18.2-month DOR with tucatinib/trastuzumab in pretreated, HER2-mutated metastatic breast cancer.

Hematology Experts Outline the Top Abstracts to Watch at the 2025 ASCO Annual Meeting

May 19th 2025

Oncology experts detail their most highly-anticipated hematology abstracts and data to watch at the upcoming 2025 ASCO Annual Meeting.

Five Under 5: Top Oncology Videos for the Week of 5/11

May 18th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

Immunotherapy Agents and ADCs May Redefine Early-Stage TNBC Management

May 18th 2025

Alexis LeVee, MD, discusses treatment challenges associated with TNBC and ongoing trials that may improve outcomes for patients with early-stage disease.

The OncFive: Top Oncology Articles for the Week of 5/11

May 17th 2025

The FDA has approved options in non–small cell lung cancer, advanced anal cancer, and pheochromocytoma or paraganglioma, and more from OncLive this week.

Cemiplimab Displays Survival Benefits Over Chemotherapy in First-Line Advanced PD-L1–High NSCLC With Brain Metastases

May 17th 2025

First-line cemiplimab extended median PFS and OS vs chemotherapy in patients with untreated advanced NSCLC with brain metastases.

T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer

May 16th 2025

T-DM1 plus palbociclib showed significant PFS in patients with HER2-positive metastatic breast cancer.

EL1SSAR Data Shed Light on Leveraging Atezolizumab Plus Nab-Paclitaxel in PD-L1+ TNBC

May 16th 2025

EL1SSAR data reinforce the importance of PD-L1 assessment to select patients with TNBC with the best outcomes on atezolizumab.

Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer

May 16th 2025

Baseline ctDNA concentration was shown to be the most significant predictor of distant recurrence-free survival in patients with early breast cancer.

Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer

May 16th 2025

Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.

Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer

May 16th 2025

Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.